A protein in blood can indicate who is at risk of diabetes at an early stage, say researchers.
"We have shown that individuals who have above-average levels of a protein called SFRP4 in the blood are five times more likely to develop diabetes in the next few years than those with below-average levels," Anders Rosengren, a researcher at the Lund University Diabetes Centre (LUDC), who led the work on the risk marker, said.
It is the first time a link has been established between the protein SFRP4, which plays a role in inflammatory processes in the body, and the risk of type 2 diabetes.
Studies at LUDC, in which donated insulin-producing beta cells from diabetic individuals and non-diabetic individuals have been compared, show that cells from diabetics have significantly higher levels of the protein.
It is also the first time the link between inflammation in beta cells and diabetes has been proven.
"The theory has been that low-grade chronic inflammation weakens the beta cells so that they are no longer able to secrete sufficient insulin. There are no doubt multiple reasons for the weakness, but the SFRP4 protein is one of them," Taman Mahdi, main author of the study and one of the researchers in Rosengren's group, said.
The level of the protein SFRP4 in the blood of non-diabetics was measured three times at intervals of three years.
Thirty-seven per cent of those who had higher than average levels developed diabetes during the period of the study. Among those with a lower than average level, only nine per cent developed the condition.
"This makes it a strong risk marker that is present several years before diagnosis. We have also identified the mechanism for how SFRP4 impairs the secretion of insulin. The marker therefore reflects not only an increased risk, but also an ongoing disease process," Rosengren said.
The marker works independently of other known risk factors for type 2 diabetes, for example obesity and age.
"If we can point to an increased risk of diabetes in a middle-aged individual of normal weight using a simple blood test, up to ten years before the disease develops, this could provide strong motivation to them to improve their lifestyle to reduce the risk," Rosengren said.
"In the long term, our findings could also lead to new methods of treating type 2 diabetes by developing ways of blocking the protein SFRP4 in the insulin-producing beta cells and reducing inflammation, thereby protecting the cells," he said.
The findings have been published in the journal Cell Metabolism.